Accurately detect stimulant use.   

Enhancing treatment outcomes through targeted screening.

Stimulants, or sympathomimetic amines, increase central nervous system activity and can be used to treat and manage attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. While some stimulants have pharmacological applications, others are categorized as Scheduled I compounds by the Drug Enforcement Agency and are often sold illicitly and abused. As a result, many professional practice guidelines recommend compliance testing in patients prescribed stimulant medications.

We now offer a targeted, high-resolution mass spectrometry screening panel that identifies and confirms the presence of 10 stimulants and phencyclidine (PCP) with a single test. Utilizing mass spectrometry in place of traditional, immunoassay testing not only increases specificity, but eliminates false positives caused by cross-reactivity with other medications. By reducing the need for additional confirmatory testing, the targeted stimulant screen saves time and money while enabling clinicians to accurately detect stimulant use and monitor compliance.

What test should I order?

TSPU | Targeted Stimulant Screen, Random, Urine

Ensure adherence to federal and state regulations by:

  • Monitoring compliance of patients prescribed stimulant(s)
  • Identifying potential illicit stimulant and PCP use

Clinical utility

  • Identifies and confirms the presence of 10 stimulants and PCP using high-resolution accurate mass spectrometry in situations where immunoassays are not adequate
  • Reduces the need for additional confirmatory testing

By the numbers


of adults use prescription stimulants in the United States annually. 1


people misused prescription stimulants in 2018. 2


reduction in substance misuse when combining clinical urine drug tests with other risk-mitigation strategies. 3

Learn how to order this test at your institution.


1 Five million American adults misusing prescription stimulants. National Institute on Drug Abuse. April 16, 2018. Accessed March 18, 2021.

2 Substance Abuse and Mental Health Services Administration. (2019). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series).

3 Argoff CE, Kahan M, Sellers EM. Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. J Opioid Manag. 2014;10(2):119–134.